嗜铬细胞瘤-副神经节瘤
Pheochromocytoma-paraganglioma
定义
一种罕见的神经内分泌肿瘤,产生于肾上腺髓质的嗜铬细胞瘤(嗜铬细胞瘤)或交感神经节和副交感神经节(副神经节瘤)。这些肿瘤最常见的是良性的,可能会产生过多的儿茶酚胺,引起高血压,有时还会引起严重的急性心血管并发症。
近两年的全球研究 433L2
2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-10开放获取Proteomic Signatures of Noise-Induced Hearing Loss in the Mouse Cochlea
- 2026-09开放获取Diagnostic yield of cancer predisposition in a nationwide prospective childhood acute leukemia cohort
- 2026-09病例报告开放获取Metastasis of lung carcinoma in a pheochromocytoma
- 2026-09荟萃分析系统综述开放获取A systematic review of cancer risks associated with MITF variants
- 2026-09病例报告开放获取A rare right perirenal hemangioma mimicking a retroperitoneal “malignant lesion”: Diagnostic and procedural challenges of an extra-renal vascular mass
- 2026-09综述开放获取Developmental Sialylation in Neuroblastoma and Neural-Crest-Derived Tumors
- 2026-09综述开放获取Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics
- 2026-09开放获取[Features of Asymptomatic Pheochromocytoma/Paraganglioma Based on Clinical-Laboratory Examination and Computed Tomography]
- 2026-09开放获取Human Y chromosome pan-organ mapping reveals progressive mosaic loss from normal to cancer
- 2026-09综述开放获取Immunological Features of Neuroendocrine Neoplasms and Adrenal Tumors
- 2026-09开放获取Clinical outcomes of HIF-2α inhibition in Von Hippel-Lindau disease: a multicenter real-world study
- 2026-08Modified Reaction Conditions for the Radiosynthesis of <sup>11</sup>C‑Labeled Asymmetrical Guanidines and the Automated Radiosynthesis of a [<sup>11</sup>C]<i>m</i>IBG Analog
- 2026-08开放获取Design, Synthesis, and Structure-Activity Relationships of Novel Piperidine-Fused Imidazolone ClpP Activators as Potential Anti-Cancer Agents
- 2026-08开放获取Delineating SWI/SNF gene and subtype expression in cancer
- 2026-08开放获取Sellar region neurocytomas exhibit a CIMP and neuroendocrine-like epigenetic signature distinct from other intra-axial neurocytomas
- 2026-08综述开放获取Theranostics in Radiation Medicine: Integrating Radiopharmaceutical Therapy and External-Beam Radiotherapy
- 2026-08开放获取GNG12 overexpression inhibits triple-negative breast cancer cell proliferation, migration, and invasion
- 2026-08开放获取Bibliometric Analysis of Whole-Body MRI from 2015 to 2025 Across Clinical Applications, Quantitative Imaging, and Artificial Intelligence
- 2026-08开放获取Prognostic and immunological value of LINC01615-related genes in kidney clear cell carcinoma: Integrated bioinformatics analysis and expression validation
- 2026-08开放获取Biomarkers of metastatic disease in pheochromocytoma and paraganglioma
境外已获批用于本病的药物 1L2
欧盟 0 项、美国 1 项。同一药物在两地各批一次的,会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。
药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。
- Iobenguane Sulfate I 131美国1994-03-25官方记录
数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
在中国开展的临床试验 20L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。
登记为可入组 8
- 招募中NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)中国研究中心 4 个:Beijing、Chengdu、Guangzhou、Shanghai
- 招募中NCT0506922018F-MFBG PET/CT in the Evaluation of Neural Crest Tumor中国研究中心 1 个:Beijing
- 招募中NCT0681374218F-mFBG PET Imaging in the Evaluation of Pheochromocytoma中国研究中心 2 个:Hangzhou
- 招募中NCT07288931Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma中国研究中心 1 个:Beijing
- 仅邀请入组NCT07182175Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors中国研究中心 1 个:Beijing
- 招募中NCT06683846Ivonescimab in the Treatment of Multiple Advanced Tumors中国研究中心 1 个:Shanghai
- 招募中NCT07195500Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma中国研究中心 1 个:Nanjing
- 尚未开始招募NCT06429397Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma中国研究中心 1 个:Guangzhou
其他状态的试验(12 项)
- 已完成NCT07412158Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)中国研究中心 1 个:Beijing
- 已完成NCT05858177The Efficacy and Safety of Temozolomide in Patients With MPPGL中国研究中心 1 个:Beijing
- 已完成NCT06669481Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics中国研究中心 1 个:Beijing
- 已完成NCT04860700The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma中国研究中心 1 个:Beijing
- 状态未知NCT04890444China Adrenal Disease Registry中国研究中心 1 个:Shanghai
- 状态未知NCT05133349A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial中国研究中心 1 个:Nanjing
- 状态未知NCT05883085A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL中国研究中心 1 个:Beijing
- 状态未知NCT05451134Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma中国研究中心 1 个:Beijing
- 状态未知NCT05752773Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma Resection中国研究中心 1 个:Beijing
- 状态未知NCT06015061Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients中国研究中心 1 个:Beijing
- 状态未知NCT05885399The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment中国研究中心 1 个:Beijing
- 状态未知NCT05885386A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL中国研究中心 1 个:Beijing
中国境外的在招试验 46L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
CT.gov 报告命中 46 项,此处取回并展示最近的 15 项。
- 尚未开始招募NCT07743138STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)美国
- 尚未开始招募NCT07714551Zanzalintinib in Unresectable and Progressive MPGGs美国
- 尚未开始招募NCT07621146A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies加拿大
- 尚未开始招募NCT07538791Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)意大利
- 尚未开始招募NCT07661420211At-MABG in Adults With Advanced Neuroendocrine Cancers美国
- 招募中NCT07680205An Experimental Study of Belzutifan Impact on Catecholamine Metabolism英国
- 尚未开始招募NCT07516275Prospective Cohort Study of Pheochromocytoma/Paraganglioma
- 招募中NCT07282587Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma美国
- 招募中NCT04119024Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors美国
- 尚未开始招募NCT07200245Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors
- 招募中NCT0650314618F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection美国
- 招募中NCT06479811[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers美国
- 招募中NCT06427798Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy美国
- 招募中NCT07072143An International Study on Pediatric Patients With Rare Tumors.意大利
- 招募中NCT06607692Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).西班牙
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)